New evidence
Protein design and engineering: four new evidence bounds
Protein Design and Engineering adds four bounds: EvoMax for wet-lab nuclease engineering, ProteinDPO aligning ESM-IF1 inverse folding to experimental stability data, DeepSCan mapping sequence to cell-surface translocation for display design, and a mammalian-display screen of thousands of AI-designed minibinders against PD-L1, CD276, and VTCN1.
Why Gives the chapter concrete wet-lab-validated bounds on what current design and scoring methods demonstrate, distinct from computational predictions alone.
Chapter Protein Design and Engineering
New evidence
ESM-3 dynamics readouts: Dyna-1 and ESMDynamic bounds
Molecular Discovery and Design adds two ESM-3 dynamics readouts: Dyna-1, trained on missing NMR assignments to mark microsecond-to-millisecond motion, and ESMDynamic, a dynamic-contact-map bound, both framed as readouts on top of ESM-3 rather than new base models.
Why Shows readers how new dynamics-prediction claims relate to the existing ESM-3 base model rather than replacing it.
Chapter Protein Structure Prediction
New evidence
RNA pseudoknot design and methylation-scoring bounds
Nucleic Acid and Genome Models adds a structure-creation bound on specified RNA pseudoknots, distinguished from viral-function claims, and Melody, which scores locus-specific DNA methylation from 10-kb genomic sequence across 39 human tissues.
Why Gives the chapter bounded examples of RNA structure design and methylation scoring rather than broader genome-regulatory claims.
Chapter Nucleic Acid and Genome Models
New evidence
Antibody-discovery and rare-variant-effect benchmark bounds
Antibody and Biologic Design adds AIntibody, a blinded prospective benchmark testing 511 designed or predicted antibodies from 29 organizations; Variant Effect Prediction adds RareEffect, an empirical-Bayes method estimating gene-level and variant-level rare-variant effect sizes.
Why Gives both chapters blinded or statistically grounded benchmarks rather than self-reported design or scoring claims.
Chapters Antibody and Biologic Design · Variant Effect Prediction
New evidence
Histopathology AI: four new benchmark and model bounds
Histopathology AI adds nnMIL, a slide-level aggregator over existing pathology foundation-model embeddings; ALPaCA, a slide-level vision-language framework trained on 35,913 whole-slide images; TRICARE, which scores risk across 2D levels inside 3D pathology volumes; and ConceptCLIP, a concept-aligned vision-language model pretrained on 23 million image-text-concept triplets.
Why Extends the chapter's evidence base across slide aggregation, visual question answering, 3D triage, and concept-aligned representation learning.
Chapter Histopathology AI
New evidence
Cell imaging and spatial-omics: six new evidence bounds
Adds VirTues (spatial-proteomics cohort bounds), MOSS (an LLM-assisted toolkit existence proof), a cryo-ET phantom with ground-truth annotations for six molecular species, scE2TM (an interpretable topic-model embedding), Bonsai (tree-based visualization with improved nearest-neighbor recovery), and a Cell Painting assay pairing PMA activation with 8,387 compounds.
Why Extends chapters covering spatial, imaging, and single-cell methods with named, source-grounded bounds on what each approach demonstrates.
Chapters Spatial Omics and Tissue Models · Microscopy and Cryo-EM AI · Single-Cell Foundation Models · Cell Painting and Image-Based Phenotyping · Toolkit for AI-Augmented Bio Research
New evidence
Therapeutics: four new evidence bounds across three chapters
Chemical Biology and Target Engagement adds VITAL, which scores peptide-protein interactions and affinity from language-model embeddings, and a MaSIF-mimicry surface-query screen of CRBN binding; Cell and Gene Therapy AI adds OptiPrime for prime-editing efficiency scoring; Drug Repurposing and Combination Therapy adds an iPSC cortical-culture phenotypic screen.
Why Gives each chapter a specific, source-grounded example of what current scoring and screening methods demonstrate in that therapeutic area.
Chapters Chemical Biology and Target Engagement · Cell and Gene Therapy AI · Drug Repurposing and Combination Therapy
New evidence
Lab automation and literature-extraction bounds
Self-Driving Labs adds GOLLuM, a calibrated Gaussian-process optimizer for next-experiment selection; Synthetic Biology Tools adds PUREdrop, a cell-free droplet screen of designed protein libraries; Knowledge Graphs and Literature AI adds PubMind, which extracts variant-function-disease associations from biomedical text.
Why Gives three chapters a calibrated optimizer, a cell-free screening method, and a literature-extraction tool as concrete evidence bounds.
Chapters Self-Driving Laboratories · Synthetic Biology Design Tools · Knowledge Graphs and Literature AI
New evidence
Science sandboxes added as a closed-loop reasoning evaluation
Benchmarks adds science sandboxes (MPRAbox, CodonBox) as a closed-loop evaluation of whether agents infer underlying rules or only raise an oracle score, noting the proposal is a preprint using damp and dry oracles.
Why Gives the chapter an evaluation design aimed at distinguishing genuine rule inference from benchmark gaming, ahead of peer review.
Chapter Benchmarks for Bio AI